AMG 510 visar lovande resultat vid behandling av KRAS-muterad lung-, och kolorektalcancer. Det visar nya data som nu presenteras på ESMO 2019. – Det är mycket hoppingivande att vi nu för första gången ser antitumöraktivitet hos patienter med kolorektalcancer med denna mutation, säger Bengt Glimelius, professor emeritus i onkologi vid Uppsala universitet och ledande expert på området.
Amgen discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.se
Gustav III:s Boulevard 54
169 27 Solna
Sverige